产品描述
| 溶解性 | Soluble in DMSO (100 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), ethanol (<1 mg/ml at 25 °C), and 30% propylene glycol, 5% Tween 80, 65% D5W (30 mg/ml at 25 °C). |
| 存贮条件 | 储存温度-20°C |
| 应用 | A potent VEGFR2 and Met inhibitor |
| 产品介绍 | Cabozantinib (XL184, BMS-907351)是一种有效的VEGFR2抑制剂，靶向作用于VEGFR2和c-Met时，IC50为0.035 nM ，也有效抑制c-Met、 Ret、 Kit、Flt-1/3/4、Tie2和AXL，IC50分别为1.3 nM， 4 nM， 4.6 nM， 12 nM/11.3 nM/6 nM， 14.3 nM and 7 nM。 |
| 备注 | Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively.Phas |
| 生化机理 | XL184 (Cabozantinib) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM. XL-184 also displays potent activity against Met, Ret, Kit, FLT1, FLT3, FLT4, Tie2, and AXL. XL184 at low concentration (0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion. |
| 别名 | BMS-907351;博卡替尼;卡博替尼;卡赞替尼;N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]苯基]-N'-(4-氟苯基)-1,1-环丙烷二甲酰胺;XL184; BMS-907351; XL-184; XL184;N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide |
